Zomedica and UXR Announce Expanded Distribution Agreement in Canada
Zomedica (OTCQB:ZOMDF) has expanded its distribution agreement with UXR Inc. to strengthen its presence in the Canadian veterinary market. Under the agreement, UXR becomes the exclusive distributor of Zomedica's PulseVet® system and VETGuardian® products in Canada, along with distribution rights for the Assisi® product portfolio.
The expansion targets a market of over 4,000 veterinary practices in Canada, with a projected 7% compound annual growth rate. The partnership aims to enhance access to Zomedica's innovative therapeutic and monitoring solutions for the country's 28 million pets, focusing on technologies that reduce pain, improve recovery, and enhance monitoring in veterinary practices.
Zomedica (OTCQB:ZOMDF) ha ampliato il suo accordo di distribuzione con UXR Inc. per rafforzare la propria presenza nel mercato veterinario canadese. In base all'intesa, UXR diventa il distributore esclusivo del sistema PulseVet® e dei prodotti VETGuardian® di Zomedica in Canada, oltre a detenere i diritti di distribuzione per la gamma di prodotti Assisi®.
L'espansione è mirata a oltre 4.000 studi veterinari in Canada, con un tasso di crescita annuo composto previsto del 7%. La collaborazione punta a migliorare l'accesso alle soluzioni terapeutiche e di monitoraggio innovative di Zomedica per i 28 milioni di animali domestici del paese, concentrandosi su tecnologie che alleviano il dolore, favoriscono la ripresa e potenziano il monitoraggio nelle strutture veterinarie.
Zomedica (OTCQB:ZOMDF) ha ampliado su acuerdo de distribución con UXR Inc. para reforzar su presencia en el mercado veterinario canadiense. Según el acuerdo, UXR se convierte en el distribuidor exclusivo del sistema PulseVet® y de los productos VETGuardian® de Zomedica en Canadá, además de contar con los derechos de distribución de la cartera de productos Assisi®.
La expansión se dirige a más de 4.000 clínicas veterinarias en Canadá, con una tasa de crecimiento anual compuesta proyectada del 7%. La asociación busca mejorar el acceso a las soluciones terapéuticas y de monitorización innovadoras de Zomedica para los 28 millones de mascotas del país, centrando esfuerzos en tecnologías que reducen el dolor, mejoran la recuperación y optimizan el seguimiento en las consultas veterinarias.
Zomedica (OTCQB:ZOMDF)는 캐나다 수의학 시장에서의 입지를 강화하기 위해 UXR Inc.와의 유통 협약을 확대했습니다. 이번 합의에 따라 UXR는 Zomedica의 PulseVet® 시스템과 VETGuardian® 제품의 캐나다 내 독점 유통업체이 되었으며, Assisi® 제품군에 대한 유통권도 확보했습니다.
확대 대상은 캐나다의 4,000개 이상 수의 진료소로, 연평균 복합 성장률이 7%로 예상됩니다. 이번 파트너십은 캐나다의 2,800만 마리 반려동물에게 Zomedica의 혁신적인 치료·모니터링 솔루션 접근성을 높이는 것을 목표로 하며, 통증 경감·회복 개선·진료실 모니터링 강화에 중점을 둔 기술들에 초점을 맞춥니다.
Zomedica (OTCQB:ZOMDF) a élargi son accord de distribution avec UXR Inc. afin de renforcer sa présence sur le marché vétérinaire canadien. Dans le cadre de cet accord, UXR devient le distributeur exclusif du système PulseVet® et des produits VETGuardian® de Zomedica au Canada, ainsi que titulaire des droits de distribution pour la gamme de produits Assisi®.
Cette extension vise un marché de plus de 4 000 cliniques vétérinaires au Canada, avec un taux de croissance annuel composé prévu de 7%. Le partenariat a pour objectif d'améliorer l'accès aux solutions thérapeutiques et de surveillance innovantes de Zomedica pour les 28 millions d'animaux de compagnie du pays, en mettant l'accent sur des technologies qui réduisent la douleur, favorisent la récupération et améliorent le suivi en pratique vétérinaire.
Zomedica (OTCQB:ZOMDF) hat seine Vertriebsvereinbarung mit UXR Inc. ausgeweitet, um seine Präsenz auf dem kanadischen Veterinärmarkt zu stärken. Gemäß der Vereinbarung wird UXR der exklusive Vertriebspartner für Zomedicas PulseVet®-System und VETGuardian®-Produkte in Kanada sowie Inhaber der Vertriebsrechte für das Assisi®-Produktportfolio.
Die Erweiterung zielt auf einen Markt von über 4.000 Tierarztpraxen in Kanada ab, mit einer erwarteten durchschnittlichen jährlichen Wachstumsrate (CAGR) von 7%. Die Partnerschaft soll den Zugang zu Zomedicas innovativen Therapie- und Überwachungslösungen für die 28 Millionen Haustiere des Landes verbessern und konzentriert sich auf Technologien zur Schmerzlinderung, verbesserten Genesung und optimiertem Monitoring in tierärztlichen Praxen.
- Access to over 4,000 Canadian veterinary practices through established distributor
- Market shows strong growth potential with 7% projected compound annual growth rate
- Exclusive distribution rights secured for key products in Canadian market
- Strategic expansion into growing Canadian pet care market with 28 million pets
- None.
Insights
Zomedica's expanded Canadian distribution enhances market access to 4,000+ vet practices with projected 7% CAGR in a pet-rich market.
Zomedica's expanded distribution agreement with UXR represents a strategic market penetration initiative into Canada's veterinary sector. The deal makes UXR the exclusive Canadian distributor for Zomedica's PulseVet system and VETGuardian products, while also distributing their Assisi therapeutic portfolio.
This agreement targets a substantial market opportunity - Canada's 4,000+ veterinary practices serving approximately 28 million pets. The Canadian pet health market is projected to grow at a
Strategically, this marks an evolution from Zomedica's previous limited approach of direct U.S.-based sales to Canadian equine veterinarians. By securing in-country distribution through UXR, Zomedica gains access to established relationships across the Canadian veterinary ecosystem, particularly in the small animal segment where they previously lacked penetration.
The agreement covers Zomedica's complete therapeutic portfolio, including their flagship PulseVet shock wave therapy system and VETGuardian remote monitoring technology. This comprehensive approach allows Zomedica to introduce their full product ecosystem rather than individual products, potentially accelerating adoption rates and creating cross-selling opportunities.
For a growth-focused veterinary health company like Zomedica, establishing strong distribution channels in adjacent markets represents a fundamental business development milestone that could meaningfully impact medium-term revenue generation without requiring the capital expenditure of direct market entry.
Agreement strengthens Canadian veterinarians' access to Zomedica's advanced therapeutic and monitoring solutions
ANN ARBOR, MI / ACCESS Newswire / September 10, 2025 / Zomedica Corp. (OTCQB:ZOMDF), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, announced today that it has expanded its distribution agreement with UXR Inc., a leading Canadian animal health company focused on supporting the needs of veterinarians across Canada.
Under the expanded agreement, UXR will become:
Exclusive distributor of Zomedica's PulseVet® system in Canada and co-exclusive distributor of the system's consumable Trode accessories.
Exclusive distributor of Zomedica's VETGuardian® products in Canada.
Distributor of Zomedica's Assisi® product portfolio in Canada, including the Assisi Loop®, DentaLoop®, Loop Lounge®, and Calmer Canine® products.
"Penetrating the Canadian small animal health market of over 4,000 veterinary practices represents an important growth opportunity for Zomedica," noted Larry Heaton, Zomedica's Chief Executive Officer. "Canadian pet parents love their 28 million pets as we do in the United States, fueling a projected
This collaboration strengthens Zomedica's ability to deliver innovative technologies that reduce pain, improve recovery, and enhance monitoring in veterinary practices throughout Canada.
Casmir Palmarella, Vice-President of UXR, added: "Our mission has always been to provide veterinarians with technologies that enhance their ability to deliver the highest level of care. By partnering with Zomedica, we are bringing proven, trusted products to clinics across Canada that will support both practitioners and pet owners."
"We are excited to partner with UXR, whose strong presence and relationships with veterinarians across Canada make them an ideal distributor for our therapeutic and monitoring solutions," said Kevin Klass, Senior Vice President of Sales at Zomedica. "Together, we will expand access to advanced tools that improve patient care, including the gold standard PulseVet® shock wave therapy and the breakthrough VETGuardian® remote monitoring system."
The agreement is effective immediately and covers distribution throughout Canada.
About UXR, Inc.
UXR Inc. is a leading Canadian distributor of veterinary equipment, with a strong reputation for innovation, reliability, and customer service. Founded in 1949, UXR is the largest independent supplier of X-Ray solutions for the veterinary market in Canada. We provide a full range of veterinary solutions including X-Ray and imaging systems, anesthesia equipment, surgical lighting, monitors, sterilizers, infusion pumps, rehabilitation, lasers, and more. For more information visit. www.uxr.ca.
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products in Canada and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on ACCESS Newswire
FAQ
What products will UXR distribute for Zomedica in Canada?
How large is Zomedica's target market in Canada?
When does the Zomedica-UXR distribution agreement take effect?
What is the growth potential for ZOMDF in the Canadian market?
Who will distribute Zomedica's PulseVet system in Canada?
